Basics |
Krystal Biotech, Inc.
Krystal Biotech Inc is a biopharmaceutical company. It uses gene therapy treatments for patients suffering from rare debilitating disorders.
|
IPO Date: |
September 20, 2017 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$4.35B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$1.81 | 2.63%
|
Avg Daily Range (30 D): |
$2.79 | 1.88%
|
Avg Daily Range (90 D): |
$2.50 | 1.75%
|
Institutional Daily Volume |
Avg Daily Volume: |
.16M |
Avg Daily Volume (30 D): |
.29M |
Avg Daily Volume (90 D): |
.28M |
Trade Size |
Avg Trade Size (Sh.): |
44 |
Avg Trade Size (Sh.) (30 D): |
32 |
Avg Trade Size (Sh.) (90 D): |
32 |
Institutional Trades |
Total Inst.Trades: |
2,049 |
Avg Inst. Trade: |
$3.81M |
Avg Inst. Trade (30 D): |
$4.86M |
Avg Inst. Trade (90 D): |
$5.27M |
Avg Inst. Trade Volume: |
.03M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$4.81M |
Avg Closing Trade (30 D): |
$6.83M |
Avg Closing Trade (90 D): |
$7.04M |
Avg Closing Volume: |
40.93K |
|
|
Financials |
|
TTM |
Q2 2025 |
Q1 2025 |
Basic EPS
|
|
$1.33
|
$1.24
|
Diluted EPS
|
|
$1.29
|
$1.2
|
Revenue
|
$
|
$ 96.04M
|
$ 88.18M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$
|
$ 38.33M
|
$ 35.73M
|
Operating Income / Loss
|
$
|
$ 39.31M
|
$ 36.18M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$
|
$ 45.06M
|
$ -36.1M
|
PE Ratio
|
|
|
|
|
|
|